StudyGraphics #VisualAbstract Melphalan 200mg/m2 Versus Reduced Doses of Melphalan in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation December 18, 2020 | Kathleen Lau Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Print RELATED ARTICLESMORE FROM AUTHOR #VisualAbstract: Avelumab does not improve outcomes in patients receiving chemoradiotherapy for squamous cell carcinomas of the head and neck #VisualAbstract: ChAdOx1 nCov-19 AstraZeneca COVID-19 vaccine not effective against B.1.351 variant #VisualAbstract: Pembrolizumab improves long-term survival in patients with stage III melanoma
